H&R Block Fiscal Q1 Adjusted Loss Widens, Revenue Rises; Fiscal 2027 Outlook Reaffirmed

MT newswire2026/11/09 20:29

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

04:29 PM EST, 11/09/2026 (MT Newswires) -- H&R Block (HRB) reported fiscal Q1 adjusted loss late Monday of $1.40 per diluted share, widening from a loss of $1.20 a year earlier. Analysts polled by FactSet expected a loss of $1.43. Revenue for the quarter ended Sept. 30 was $224.3 million, compared with $203.6 million a year earlier. Four analysts expected $212.3 million. The company said it continues to expect fiscal 2027 adjusted diluted earnings between $6.04 to $6.24, along with revenue in the range of $4.11 billion to $4.16 billion. The analysts expect $6.14 and $4.13 billion, respectively.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.

华尔街见闻•2026/11/09 22:12